190 likes | 327 Views
Implementing the Leapfrog Standard for β -Blocker Use during AAA Repair in California Hospitals: Translation of Evidence-Based Process Measures to Improve Surgical Outcomes. Benjamin S. Brooke, MD
E N D
Implementing the Leapfrog Standard for β-Blocker Use during AAA Repair in California Hospitals: Translation of Evidence-Based Process Measures to Improve Surgical Outcomes Benjamin S. Brooke, MD Francisca Dominici, PhD; Martin A. Makary, MD MPH; Bruce A. Perler, MD; & Peter J. Pronovost, MD PhD Johns Hopkins School of Medicine and Bloomberg School of Public Health, Baltimore, MD AcademyHealth Annual Research Meeting, June 10, 2008
Translation of Leapfrog Group Evidence-Based Standards • Purpose • Scope • Implementation • Evaluation • Results • Dissemination • Lessons Learned • Next Steps
Leapfrog Group Hospital Quality & Patient Safety InitiativePurpose • Founded in 2000 by consortium of large public and private health care purchasers • Establish and promote evidence-based standards (“leaps”) • Computerized Physician Order Entry (CPOE) • 24-Hour ICU Physician Staffing • Evidence-Based Hospital Referral (EBHR) standards for 5 High Risk Operations
Abdominal Aortic Aneurysm (AAA) Repair • AAA prevalent in 3-9% of U.S. population over the age of 65. • More than 40,000 prophylactic AAA repairs undertaken each year to prevent rupture & sudden death from occurring. • 30-day mortality for elective open AAA repair ranges between 4-6%.
Leapfrog Evidence-Based Standards for AAA Repair • Hospital AAA Case Volume • Established in 2000 • Minimum of 50 elective cases per year • Supported by observational cohort studies • Routine Perioperative Beta-blocker Use • Established in 2003 • 80% of patients need to be on therapy during hospitalization & at discharge • Supported by randomized controlled trials
The Leapfrog Group InitiativeScope • Nationwide - regional “rollout waves” • Metropolitan and State-wide “lily pads” • Annual Leapfrog Group Hospital Quality & Patient Safety Survey • First survey: June 2001 • Atlanta, Tennessee, Minnesota, Seattle, St. Louis, California • 1,300 U.S. hospitals participating to date
California • 337 urban & suburban hospitals targeted • Diverse/representative patient populations • California Office of Statewide Health Planning & Development (OSHPD) Discharge Database
Translating Leapfrog Standards into Hospital PolicyImplementation • Incentives/Rewards: • Public Recognition • Different Financial Incentives • Improvements in Clinical Outcomes • Reduce Health Care Costs • Potential Barriers • Infrastructure Requirements • Capital Investment • Change in Hospital Culture • Controversial Standards
Implementing Routine β-blocker Use During AAA Repair • Advantages of Process Measure • Widely used medication in clinical practice • Target population are good candidates • Limited side effects and risks • Inexpensive • Limitations of Process Measure • Some patients may not tolerate therapy • Requires titration for maximal benefit • Patients may require extra monitoring
Hospital Compliance with Leapfrog β-blocker StandardEvaluation • 212 California hospitals returned Leapfrog Group surveys (63% response rate) • 140 California hospitals performed elective AAA repairs • 37 (26%) Met Leapfrog β-blocker Standard • 103 (74%) Did Not Meet β-blocker Standard
Evaluating the Impact of Adopting β-blocker Policy • Survey response data linked to the OSHPD patient discharge database • In-hospital mortality compared over 2 periods: • 2000-2002: Pre β-blocker • 2003-2005: Post β-blocker • Poisson regression rate ratio estimates for in-hospital mortality
Hospital CharacteristicsResults *Admissions reported in units of thousands
Characteristics of Patients * P<0.05 for comparison within groups over time
Mean In-Hospital Death Rate Mean Deaths Per 100 AAA Repairs Years Source: California OSHPD dataset between years 1998 to 2005
Poisson Regression Rate Ratio Estimates for In-Hospital Mortality Ratio of Rate Ratios Hospitals RRR (95% CI) P-value Hospitals without β-Blocker (n=103) 1.00 (Reference) Hospitals with β-Blocker Policy (n=37) Random Effects Unadjusted 0.69 (0.42 to 1.45) 0.153 Random Effects Adjusted * 0.50 (0.26 to 0.96) 0.038 Fixed Effects Unadjusted 0.67 (0.40 to 1.12) 0.129 Fixed Effects Adjusted * 0.43 (0.20 to 0.92) 0.030 * Adjusted for race, insurance, gender, age, Charlson index, AAA volume & ICU admissions.
Bridging the Gap in TranslationDissemination • Leapfrog Group Strategy • Centers of Excellence • Pay for Participation • Pay for Performance • Regional Collaboratives • Regional networks of hospitals with robust evaluation of compliance & outcomes • e.g. Michigan Keystone initiative
β-blocker Use in California Hospitals Lessons Learned • Hospitals may achieve significant improvements in patient outcomes by adopting a single evidence-based measure • There is still low overall compliance with adopting process measures • More efforts are needed to optimize the compliance and dissemination of proven evidence-based practices
Translation of Leapfrog Evidence-Based Standards Next Steps • CMS MEDPAR dataset • Evaluate Impact of Hospital Compliance with Other Leapfrog Standards • Identify other Evidence-Based Process Measures
Acknowledgments • Aidan McDermott • JHSPH Dept of Biostatistics • Sarah Collins • Leapfrog Group • Dennis Bush • Thompson Healthcare